# Associations of Prenatal Cannabis Exposure and Neonatal Brain Development in the HBCD Cohort

Leela Shah[1,2], Elizabeth M. Planalp[1], Ryan McDonald[3], Caitlin J, Regner[4], Sreevalli Atluru[4], Andrew L. Alexander[1,5,6], Pilar N. Ossorio[7,8,9], Julie Poehlmann[10], Douglas C. Dean[1,5,11]

Corresponding Author: Leela Shah

(leela.shah@wisc.edu | 757-749-6173 | 1500 Highland Ave, Madison, WI, 53705)

[1]Waisman Center, University of Wisconsin–Madison, 1500 Highland Ave, Madison, WI 53705, USA
[2]Neuroscience Training Program, University of Wisconsin–Madison, 1111 Highland Ave, Madison, WI 53705, USA
[3]Obstetrics and Gynecology, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[4]Family Medicine and Community Health, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[5]Medical Physics, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA.
[6]Psychiatry, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[7]School of Law, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[8]Morgridge Institute for Research, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[9]Department of Medical History and Bioethics, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[10]Human Development and Family Studies, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA
[11]Pediatrics, University of Wisconsin–Madison, 600 Highland Ave, Madison, WI 53792, USA

Manuscript word count: 2,956 words

Key Points

Question: Is prenatal cannabis exposure associated with brain development in the first month of life?

Findings: In a cohort of 1,782 mother–infant dyads, prenatal cannabis exposure was associated with region-specific differences in neonatal brain volumes. Brain volume and diffusion white matter microstructure associations differed between exposure limited to the first trimester versus exposure that continued into the third trimester. Greater frequency of exposure across gestation was also associated with volumetric and microstructural differences.

Meaning: The timing and frequency of prenatal cannabis exposure is associated with alterations in neonatal brain development, underscoring the importance of addressing cannabis use in pregnancy.

Abstract

Importance: Prenatal cannabis exposure is increasing in prevalence, yet its associations with early brain development—particularly how the timing and frequency of exposure across gestation relate to neonatal brain structure—remain insufficiently understood. Clarifying these associations is essential for informing early risk identification and guiding perinatal care.

Objective: To examine associations between patterns of maternal prenatal cannabis exposure, including exposure presence, gestational timing, and frequency of exposure, and neonatal brain structure and microstructure during the first month of life.

Design, Setting, and Participants: This cohort study included 1,782 mother–infant dyads (221 with PCE) from the HEALthy Brain and Child Development Study. Mother-reported prenatal cannabis exposure was assessed using the validated Timeline Follow-back method. Infants underwent natural-sleep magnetic resonance imaging, including T2-weighted structural imaging and diffusion imaging, within the first month of life.

Main Outcomes and Measures: Associations between prenatal cannabis exposure and regional T2-weighted volumes and diffusion white matter microstructure metrics examined (1) exposure presence, (2) gestational timing of exposure, and (3) frequency of exposure within exposed infants.

Results: Any prenatal cannabis exposure was associated with brain volume differences in cerebellar and subcortical limbic regions, including smaller amygdala, thalamic, and cerebellar vermis volumes and larger caudate, hippocampal, and cerebellar cortex

volumes. Timing-specific analyses revealed divergent patterns: first trimester exposure was associated with smaller volumes in select regions, whereas exposure that continued into the third trimester was associated with larger volumes in overlapping structures, with additional subcortical volumetric differences observed. White matter microstructure alterations were observed only among infants with exposure that continued into the third trimester. Within the exposed subgroup, higher frequency of cannabis exposure was associated with larger cerebral white matter volumes and white matter microstructural differences in white matter regions.

Conclusions and Relevance: In infants with maternal prenatal cannabis exposure, we observed timing- and frequency-dependent differences in brain development within the first month of life. These findings underscore the importance of considering not only the presence of exposure, but also when and how much cannabis is used during pregnancy to support targeted prenatal counseling and early developmental monitoring for exposed infants.

## Introduction

As restrictions on cannabis availability have decreased across the United States, overall rates of use have increased [2]. This rise spans demographic groups, including pregnant individuals, among whom prenatal cannabis use is estimated at 8% [3]. Cannabis may be perceived as a natural remedy for pregnancy-related symptoms and anxiety, driving use in this population [4]. Beyond adverse perinatal outcomes such as low birth weight, prematurity, and placental pathologies [5], prenatal cannabis exposure (PCE) has been associated with neurodevelopmental sequelae, including autonomic instability and seizures in newborns [5,6], as well as memory deficits, impulsivity, hyperactivity, and increased addiction vulnerability in adolescents [7,8]. Despite these associations, the neurobiological mechanisms underlying PCE-related outcomes remain incompletely understood.

Preclinical studies indicate that cannabinoids can disrupt the developing endocannabinoid system, which plays a critical role in early neurodevelopment, including neuronal migration, axon guidance, and synaptogenesis [8–11]. Cannabinoid receptor expression begins early in gestation (approximately 5–6 weeks) in brain regions including the prefrontal cortex, mesolimbic system, striatum, cerebellum, and hypothalamic–pituitary axis [8,9,12]. As these receptors mature and function throughout gestation, PCE may differentially affect neurodevelopment depending on when and how frequently the exposure occurs and whether it persists across gestation[13]. However, animal and cellular models cannot fully capture the complex pharmacokinetics of PCE [14,15].

Human neuroimaging studies have shown associations between PCE and the development of the cerebellum[16], cortex[16–18], fronto- and meso-limbic structures (e.g., the insula and fornix) [18,19,21], white matter relay regions (e.g., the internal capsule) [17,19,20], and basal ganglia [16]. Yet, most studies are conducted during adolescence, when retrospective reports of cannabis use, potential postnatal cannabis exposures, and other life experiences may affect the measured association between PCE and neurodevelopment[18–20]. Critically, the existing literature inadequately models timing and frequency associations relevant to PCE. Epidemiologic investigations suggest that PCE continuing beyond the first and second trimesters confers greater risk for adverse neurodevelopmental and behavioral outcomes [17,19,21]. Albeit in limited samples, infant neuroimaging work further indicates regionally specific alterations in brain growth trajectories, with accelerated growth in rapidly developing regions and slowed growth in other regions that appears dose dependent [17]. The few existing infant neuroimaging studies of PCE remain limited in sample size and in their ability to model clinically relevant patterns of exposure or broader contextual sociodemographic and psychosocial influences [22]. These findings underscore the need to explicitly examine timing- and frequency-dependent associations of PCE and neurodevelopment within large samples.

The current study leverages data from the HEALthy Brain and Child Development (HBCD) Study, a large-scale longitudinal study of brain development in the U.S. [23,24]. HBCD aims to address challenges in studying prenatal substance exposure, including stigma, legal concerns, and underreporting [25,26]. Its trauma-informed approach supports accurate disclosure and retention across diverse populations [27,28]. Here, we examined

associations between patterns of maternal PCE, including presence, gestational timing, and frequency of exposure, and measures of neonatal gray matter structure (T2-weighted regional brain volumes) and white matter microstructure (diffusion tensor imaging metrics), while accounting for key sociodemographic factors.

## Methods

### Study Design and Participants

This observational cohort study analyzed data from 1,782 mother-infant dyads from the HBCD Study Data Release 2.0 [29,30] with complete prenatal assessment and neonatal MRI data (221 with PCE). Pregnant participants completed standardized prenatal assessments during the second or third trimester. Infants underwent MRI scanning in the first month of age during natural sleep using harmonized multisite protocols [23]. Written informed consent was obtained from all participants, and study procedures were approved by local institutional review boards and the centralized HBCD Institutional Review Board at the University of California, San Diego. Detailed cohort and imaging methods are described elsewhere [23,24]. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline [31].

### PCE Quantification and Covariates

Prenatal substance exposure was assessed through maternal self-report using the validated HBCD Modified ASSIST [32] instrument for screening, which screened for any substance use during pregnancy. Participants who screened positive completed the Timeline Follow Back (TLFB, eFigure 1 in the Supplement) [33–35], which captured the

number of uses per week across seven sampled weeks spanning gestation. PCE was defined as any maternal prenatal cannabis use during at least 4 of the 7 TLFB-assessed weeks [36]. This threshold was selected a priori to distinguish sustained exposure from isolated or sporadic exposure and is consistent with prior HBCD analytic workflows [36]. Within dyads meeting the PCE threshold, first-trimester-limited PCE was defined as any reported maternal cannabis use occurring between two and six weeks after the last menstrual period. Sustained PCE persisting into the third trimester was defined as early reported use in combination with reported use during the two weeks immediately preceding delivery. Frequency of exposure was defined as the total number of maternally reported cannabis use episodes across the seven TLFB-assessed weeks. Maternal mental health symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS) [37] and the Diagnostic and Statistical Manual of Mental Disorders, 5$^{th}$ Edition (DSM-5) Self-Rated Cross-Cutting Anxiety Measure Level 1 [38]. Additional covariates included maternal age, educational attainment, household income, and maternal prenatal nicotine (≥ 4 weeks of exposure), alcohol (≥ 4 weeks of exposure), or opioid exposure (≥ 2 weeks of exposure). Infant sex and corrected gestational age at MRI were included in all models.

Neuroimaging Acquisition, Processing, and Harmonization

Neonatal MRI data were acquired on 3T Siemens, General Electric, or Philips scanners using harmonized HBCD infant protocols optimized for natural sleep [23]. Analyses focused on T2-weighted structural MRI and diffusion MRI (dMRI). All imaging data underwent centralized quality control and preprocessing by the HBCD Data Coordinating Center. BIBSNet is a deep learning model optimized for infant MRI brain

tissue segmentation [39] and was used to generate native-space T2-weighted brain segmentations and masks, while dMRI data were processed with QSIRecon (QSIRecon-DIPYDKI pipeline) [40] to correct for motion, eddy currents, EPI distortions, and gradient nonlinearity and derive voxelwise DTI metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). Anatomical ROIs for T2-weighted images were derived from BIBSNet segmentations, and white matter ROIs for diffusion metrics were automatically segmented into canonical bundles using the HCP1065 population tractography atlas [41]. Diffusion and volumetric neuroimaging measures were harmonized across acquisition sites using ComBat, an empirical Bayes method that removes systematic batch effects while preserving biological variability, using the sva package in R [42]. Site (scanner) was modeled as the batch variable, and biological covariates of interest (cannabis exposure, sex, and age [and total brain volume, where applicable]) were included in the design matrix to ensure that variance associated with these factors was retained during harmonization. Harmonized values were then used in all subsequent statistical analyses.

Region Selection and Data Preparation

Analyses targeted brain regions previously implicated in PCE and early neurodevelopment [1,43], including meso- and fronto-limbic structures (amygdala, hippocampus, nucleus accumbens), basal ganglia and thalamus, cerebral white matter and association tracts (corpus callosum, superior and inferior longitudinal fasciculi, cingulum, uncinate fasciculus), and cerebellar structures (gray and white matter, peduncles, and vermis). For bilaterally paired structures, hemispheric differences were

evaluated using paired t-tests; in the absence of significant asymmetry, values were averaged. Neuroimaging metrics were winsorized to three standard deviations above or below the mean to account for outlier values.

Statistical Analysis

Analyses were conducted in RStudio [44]. Group differences in demographic and clinical variables were assessed using independent samples t-tests and Pearson correlations. Covariate-balanced propensity scores (CBPS) were estimated using the CBPS package to balance sociodemographic variables, maternal mental health symptoms, and co-occurring substance exposures [45–47]. Covariate balance before and after propensity score weighting is shown in Supplemental eFigure 2. Linear regression models were then used to evaluate associations between PCE and neonatal MRI outcomes across three analytic frameworks: (1) PCE presence in the full sample; (2) timing of PCE (first trimester versus sustained) in the full sample; and (3) frequency of PCE (only within the PCE subgroup). For (3), the CBPS package was used to balance sociodemographic covariates within the PCE subgroup by estimating a generalized propensity score for PCE frequency (eFigure 3 in the Supplement) [45], and the PCE frequency variable was log-transformed to address skewness, consistent with guidance from a Box-Cox transformation analysis [48,49]. All models were adjusted for infant sex and age at scan (corrected to 40 weeks' gestation), with propensity scores applied as weights. Volumetric models were adjusted for total brain volume. Effect sizes (partial eta squared – $\eta^2p$), regression coefficients, and false discovery rate-corrected P-values ($P_{corr}$) were reported. Of 2,310 eligible dyads in HBCD Data Release 2.0, 1,782 had complete prenatal assessment and neonatal MRI data and were included in analyses. Given the

sample size (N = 1,782 for volumetric analyses; N = 1,394 for diffusion analyses) and approximately 11 to 12 covariates per model, the study had greater than 80% power to detect small effect sizes (Cohen $f^2 \approx 0.01$; $\eta^2p \approx 0.01$) at a 2-sided $\alpha = .05$.

## Results

Of the 1,782 mother–infant dyads with volumetric MRI data, 221 infants had PCE. Diffusion MRI data were available for 1,394 dyads, including 175 with PCE. 3 dyads were excluding from the timing analyses due to late PCE without early PCE. Compared with non-exposed dyads, mothers reporting PCE had lower household income and educational attainment, were younger at childbirth, and reported higher prenatal nicotine and alcohol exposure (all $p < .05$; Table 1). Subclinical or clinical depressive symptoms (EPDS ≥10) were reported by 370 mothers; mild or greater anxiety symptoms (APA Cross-Cutting Anxiety, Level 1 > 1) were reported by 357 mothers.

[Table 1]

### Prenatal Cannabis Exposure and Neonatal Brain Structure

In full-sample analyses, PCE presence was associated with volumetric differences in several cerebellar and subcortical limbic regions (Figure 1, $p_{corr} < .05$). Specifically, PCE was associated with larger volumes in the left cerebellar cortex, left hippocampus, and left caudate; and smaller volumes in the right nucleus accumbens, right amygdala, right cerebellar vermis, and left thalamus. Effect sizes were largest ($\eta^2p > .01$) in regions where PCE was associated with smaller volumes. No significant associations were observed between PCE presence and diffusion MRI metrics.

[Figure 1]

Gestational Timing of PCE

Timing-specific analyses compared infants with first trimester PCE to those with sustained PCE (Figure 2). These groups showed opposing volumetric associations across overlapping regions. First trimester exposure was associated with smaller right amygdala volumes and larger left cerebellar cortex volumes, whereas sustained PCE was associated with larger right amygdala volumes and smaller left cerebellar cortex volumes. Effect sizes were largest ($\eta^2p > .01$) in regions showing smaller volumes with first trimester PCE and larger volumes with sustained PCE.

Additional timing-specific associations were observed in subcortical regions. First trimester PCE was associated with smaller left thalamic volume, whereas sustained PCE was associated with larger volumes in the left cerebral white matter, left caudate, and left hippocampus; and smaller volumes in the left pallidum and left nucleus accumbens.

Diffusion MRI analyses revealed timing-specific microstructural associations limited to infants with sustained PCE. Sustained PCE was associated with lower MD and RD in the superior cerebellar peduncle and higher AD, MD, and RD in association and commissural regions, including the cingulum, inferior longitudinal fasciculus, superior longitudinal fasciculus, uncinate fasciculus, and corpus callosum. No significant diffusion associations were observed for first trimester PCE.

[Figure 2]

Frequency-Dependent Associations Within the PCE Subgroup

Within the PCE -exposed subgroup, greater frequency of exposure was associated with larger left cerebral white matter volume and lower FA in the right uncinate fasciculus ($\eta^2p > .01$, Figure 3).

Across analyses, infant age (corrected to a 40-week gestation) and sex were included as covariates. Infant sex did not moderate associations between PCE and brain measures, and nonsignificant interaction terms were removed to improve model fit based on AIC.

[Figure 3]

**Discussion**

Increasing rates of PCE have raised clinical and public health concerns [50], yet its associations with early brain development, particularly regarding timing and frequency of exposure, are uncharacterized [51,52]. Using data from a large, multi-site study, we found that maternal PCE was associated with statistically significant differences in neonatal brain structure across cerebellar, cortical, subcortical, and white matter regions (Figure 4). Associations varied by gestational timing and persistence of exposure, underscoring limitations of binary exposure definitions and highlighting the importance of developmental context when evaluating neurodevelopmental correlates of PCE [53].

[Figure 4]

In full-sample analyses, PCE was associated with volumetric differences primarily in cerebellar and mesolimbic regions, with larger effects observed for regions showing smaller volumes, a pattern likely reflecting relative sensitivity rather than absolute magnitude of difference. Implicated regions are associated with functional connectivity differences in infants with PCE [16], and overlap with known fetal cannabinoid receptor distributions [54], suggesting perturbation of endocannabinoid-related neurodevelopmental processes [52].

Analyses revealed distinct timing- and region-specific associations. First trimester PCE occurring largely pre-pregnancy recognition was associated with smaller amygdala volumes and larger cerebellar cortex volumes, whereas sustained PCE that continued into the third trimester was associated with opposite patterns in these same regions. The hippocampus, nucleus accumbens, and striatum demonstrated volumetric differences only with persistent exposure. Thus, discontinuation after pregnancy recognition is associated with a distinct neurodevelopmental profile compared with continued use, suggesting gestational timing–specific deviations in regional growth trajectories [13,55,56].

White matter microstructural associations similarly varied by PCE timing. Diffusion MRI alterations were not associated with PCE presence or first trimester PCE and were observed only among dyads with sustained PCE that continued into the third trimester. Alterations included lower diffusivity in cerebellar white matter and higher diffusivity in major association and commissural tracts, including the corpus callosum, cingulum, superior longitudinal fasciculus, and uncinate fasciculus. Given that white matter

organization continues to mature well beyond the neonatal period [57–59] these findings may represent early microstructural differences that precede later-emerging alterations in connectivity or function as the white matter continues to develop postnatally [56]. The variability in directionality of findings supports preclinical evidence that PCE is associated with microstructural organizational changes rather than gross cellular loss alone [60]. Our findings indicate that continued PCE after pregnancy recognition is associated with neurodevelopmental differences beyond PCE limited to the first trimester, highlighting that cessation counseling may be beneficial both before pregnancy planning and after pregnancy recognition.

Within the cannabis-exposed subgroup, greater frequency of PCE was associated with larger left cerebral white matter volumes and lower FA in select tracts, suggesting associations may scale with PCE frequency or duration. Frequency-dependent associations did not uniformly align with the direction of timing-specific effects, underscoring the complexity of interpreting early brain volume differences. This pattern of frequency-dependent associations aligns with previously reported dosage-dependent associations with PCE and infant brain development [17]. Importantly, larger brain volume should not be interpreted as reflecting more optimal development, nor does smaller volume necessarily indicate neurotoxicity. Rather, neonatal volumetric deviations likely reflect altered developmental processes whose clinical significance depends on region, timing, and broader developmental context. Longitudinal data will be essential to determine whether these early associations persist, normalize, or predict later functional outcomes.

Limitations

Several limitations warrant consideration. Despite using covariate-balanced propensity scores, residual confounding remains possible, particularly from unmeasured psychosocial, environmental, or biological factors associated with PCE [61]. Maternal PCE measures were necessarily coarse; we were unable to precisely distinguish exposure occurring before versus after pregnancy recognition, quantify dose per use, assess for associations of late-gestation-only PCE, or account for cannabis potency or mode of administration. As the TLFB samples 7 weeks across pregnancy, we cannot account for possible changes in use outside of the sampled weeks (e.g., second trimester exposure). Misclassification of PCE timing or intensity may therefore have attenuated or distorted observed associations. Additionally, neonatal T2-weighted volumetric measures and diffusion tensor imaging provide non-specific indices of underlying neurobiology [62], limiting inferences regarding developmental processes such as axonal growth or myelination [57,63,64]. Finally, analyses are cross-sectional and only include maternal data, precluding conclusions about paternal PCE, developmental trajectories, or functional associations of PCE.

## Future Directions

Longitudinal follow-up within HBCD will be critical to understand how brain differences relate to later cognitive, socioemotional, and motor outcomes, to identify periods of heightened vulnerability or resilience [65,66]. Advanced imaging approaches, such as neurite orientation dispersion and density imaging [67–69] and quantitative relaxometry [57,70], may further elucidate the neurobiology underlying PCE -related differences.

## Conclusions and Clinical Implications

Leveraging a large, well-phenotyped prenatal substance exposure cohort with harmonized multimodal neuroimaging data, we examined how patterns of maternal PCE are associated with early brain development. PCE was associated with significant neonatal brain structural differences that varied by gestational timing and frequency of exposure. First trimester PCE was linked to volumetric variation in select cerebellar and subcortical regions, whereas PCE that continued into the third trimester was associated with differing volumetric patterns in overlapping regions, along with white matter microstructural alterations. Greater frequency of PCE demonstrated additional associations, supporting a timing- and frequency-dependent framework. Rather than interpreting volumetric and microstructural differences as inherently adaptive or maladaptive, we situate these findings within a developmental framework in which variation from typical trajectories may reflect altered neurodevelopmental pathways. Longitudinal follow-up will be essential to clarify how these early differences relate to later functional outcomes and to identify opportunities for supportive intervention [17,71,72].

From a clinical perspective, these findings underscore the importance of developmentally informed counseling regarding cannabis exposure across pregnancy, including attention to timing and frequency of use [73]. Our results highlight that neurodevelopmental profiles may differ depending on whether exposure occurs prior to or continues after pregnancy recognition, suggesting potential value in supporting individuals who choose to modify or discontinue use once pregnancy is identified [4,26,50,74]. Although PCE was associated with neonatal brain differences in this study, current evidence and guidelines do not support prenatal or perinatal cannabis exposure as an absolute contraindication to breastfeeding [73,75]. Ultimately, supportive,

nonjudgmental communication that promotes accurate disclosure and shared decision-making is essential to reduce stigma and optimize maternal and infant health.

**Table 1. Sample Demographic Characteristics of Mother-Child Dyads with and Without PCE**

| **Characteristic** | **No PCE N = 1,561[1]** | **PCE N = 221[1]** | ***P*-value[2]** |
|---|---|---|---|
| Median Household Income Bracket (USD) | $75,000 - $99,999 | $10,000 - $24,999 | < .0001 |
| Educational Attainment (Years) | 17.14 (2.7) | 14.30 (2.4) | < .0001 |
| Birth Mother Age (Years) | 32.5 (5.4) | 29.3 (5.7) | < .0001 |
| % with Nicotine Exposure | 6.9% | 46% | < .0001 |
| % with Alcohol Exposure | 4.6% | 14% | < .0001 |
| % with Opioid Exposure | 3.4% | 12% | < .0001 |
| % with First Trimester Cannabis Exposure | -- | 68% | < .0001 |
| % with Sustained Cannabis Exposure | -- | 30% | < .0001 |
| Cannabis Exposure Frequency (# Reported Uses over 7-week TLFB) | 1.4 (8.6) | 103.1 (107.8) | < .0001 |
| Edinburgh Postnatal Depression Score | 5.5 (4.6) | 8.6 (6.1) | < .0001 |
| APA Cross-Cutting Anxiety, Level 1 | 1.30 (1.2) | 2.05 (1.4) | < .0001 |
| Infant Age at MRI (Prematurity - Adjusted, Weeks) | 3.06 (1.8) | 3.01 (2.1) | .499 |
| Infant Gestational Age at Birth (Weeks) | 37.97 (1.8) | 37.82 (1.7) | .035 |
| Infant Sex | 689 F / 794 M (78 unknown) | 105 F / 106 M (10 unknown) | .687 |

[1] *Mean (SD)*
[2] *Welch Two Sample t-test, Pearson's Chi-squared test*

**Figure 1. Associations Between PCE Presence and Regional Brain Measures**
*Significant associations between PCE presence and T2-weighted volumes across regions of interest are shown. Forest plots show parameter estimates (ß) for associations between PCE presence and regional brain measures. Points represent ß for statistically significant associations only ($P_{corr} < .05$), and brackets represent 95% confidence intervals for ß values. Parameter estimates (ß), partial eta squared ($\eta^2p$) and FDR-corrected p values ($P_{corr}$) are reported in eFigure 4 in the Supplement.*



**Figure 2. Associations Between PCE Timing and Regional Brain Measures**

*Significant associations between First Trimester PCE and/or Sustained PCE and T2-weighted volumes and DTI Metrics across regions of interest are shown. Forest plots show parameter estimates (ß) for associations between PCE timing and regional brain measures. Points represent ß for statistically significant associations only ($P_{corr} < .05$), and brackets represent 95% confidence intervals for ß values. Parameter estimates (ß), partial eta squared ($\eta^2p$) and FDR-corrected p values ($P_{corr}$) are reported in eFigure 5 in the Supplement.*



**Figure 3. Associations Between Frequency of PCE and Regional Brain Measures**

*Significant associations between frequency of PCE and T2-weighted volumes and DTI Metrics across regions of interest are shown. Parameter estimates (ß), Partial eta squared ($\eta^2p$), and FDR-corrected p values ($P_{corr}$) are reported.*



**Figure 4. Brain Regions Implicated Across PCE Presence, Timing, and Frequency Models**

*Left panel shows gray matter regions in which T2-weighted volumes were associated with PCE. Right panel shows white matter regions in which DTI metrics were associated with PCE. Figure created in BioRender. Shah, L. (2026) https://BioRender.com/2k8k567*



Acknowledgement: We extend our sincere gratitude to the families who generously participated in this study, and to the students and research staff whose dedication and expertise made the collection of these data possible.

Data Availability Statement: Data used in the preparation of this article were obtained from the HEALthy Brain and Child Development (HBCD) Study, held in the NIH Brain Development Cohorts Data Sharing Platform. This is a multisite, longitudinal study designed to recruit approximately 7,000 families and follow them from pregnancy to early childhood. The HBCD Study is supported by the NIH and additional federal partners under award numbers U01DA055352, U01DA055353, U01DA055366, U01DA055365, U01DA055362, U01DA055342, U01DA055360, U01DA055350, U01DA055338, U01DA055355, U01DA055363, U01DA055349, U01DA055361, U01DA055316, U01DA055344, U01DA055322, U01DA055369, U01DA055358, U01DA055371, U01DA055359, U01DA055354, U01DA055370, U01DA055347, U01DA055357, U01DA055367, U24DA055325, and U24DA055330. A full list of supporters is available at Federal Partners-HBCD Study. A full list of participating sites is available at Study Sites-HBCD Study. HBCD Study Consortium investigators designed and implemented the study and/or provided data but did not necessarily participate in the analysis or writing of this report. This manuscript reflects the views of the authors and may not reflect the opinions or views of the NIH or the HBCD Study Consortium investigators. The HBCD dataset grows and changes over time. The HBCD data used in this report came from [https://doi.org/10.82525/vnye-pe87]. DOIs can be found at [https://www.nbdc-datahub.org/hbcd-study]. Corresponding author Leela Shah

had access to all data required for this investigation through an approved Data Use Certificate. R Scripts used to conduct this analysis are available at https://github.com/Developing-Brain-Imaging-Lab/Prenatal-Cannabis-Brain-Development-HBCD-Cohort.

References

1. Shah L, Yoon CD, LaJeunesse AM, et al. Prenatal substance exposure and infant neurodevelopment: a review of magnetic resonance imaging studies. *Front Hum Neurosci*. 2025;19. doi:10.3389/fnhum.2025.1613084

2. Martins SS, Levy NS, Bruzelius E, Segura LE. Cannabis legalization in the US. Where do we go from here? *Trends Psychiatry Psychother*. 2022;44:e20220001. doi:https://doi.org/10.47626/2237-6089-2022-0001

3. Substance Abuse and Mental Health Services Administration [SAMHSA]. *Substance Abuse and Mental Health Services Administration: Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health.* Center for Behavioral Health Statistics and Quality; 2020. https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report

4. Vanstone M, Taneja S, Popoola A, et al. Reasons for cannabis use during pregnancy and lactation: a qualitative study. *CMAJ Can Med Assoc J*. 2021;193(50):E1906-E1914. doi:10.1503/cmaj.211236

5. Krishnan P, Yen E. The changing landscape of cannabis use: impact on maternal health and neonatal outcomes. *Pediatr Res*. Published online June 20, 2025:1-11. doi:10.1038/s41390-025-04209-4

6. Martin GI. Marijuana: the effects on pregnancy, the fetus, and the newborn. *J Perinatol*. 2020;40(10):1470-1476. doi:10.1038/s41372-020-0708-z

7. De Genna NM, Willford JA, Richardson GA. Long-term effects of prenatal cannabis exposure: Pathways to adolescent and adult outcomes. *Pharmacol Biochem Behav*. 2022;214:173358. doi:10.1016/j.pbb.2022.173358

8. Rodrigues RJ, Marques JM, Köfalvi A. Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence. *Cells*. 2024;13(22):22. doi:10.3390/cells13221875

9. Fride E. Multiple Roles for the Endocannabinoid System During the Earliest Stages of Life: Pre- and Postnatal Development. *J Neuroendocrinol*. 2008;20(s1):75-81. doi:10.1111/j.1365-2826.2008.01670.x

10. Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. *Trends Pharmacol Sci*. 2007;28(2):83-92. doi:10.1016/j.tips.2006.12.004

11. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. *Eur J Neurosci*. 2003;17(9):1747-1754. doi:10.1046/j.1460-9568.2003.02599.x

12. Keimpema E, Mackie K, Harkany T. Molecular model of cannabis sensitivity in developing neuronal circuits. *Trends Pharmacol Sci*. 2011;32(9):551-561. doi:10.1016/j.tips.2011.05.004

13. Wu CS, Jew ,Christopher P, and Lu HC. Lasting Impacts of Prenatal Cannabis Exposure and the Role of Endogenous Cannabinoids In the Developing Brain. *Future Neurol*. 2011;6(4):459-480. doi:10.2217/fnl.11.27

14. Chayasirisobhon S. Mechanisms of Action and Pharmacokinetics of Cannabis. *Perm J*. 2021;25(1):1-3. doi:10.7812/TPP/19.200

15. Monfort A, Ferreira E, Leclair G, Lodygensky GA. Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. *Front Pharmacol*. 2022;13. doi:10.3389/fphar.2022.919630

16. Grewen K, Salzwedel AP, Gao W. Functional Connectivity Disruption in Neonates with Prenatal Marijuana Exposure. *Front Hum Neurosci*. 2015;9. doi:10.3389/fnhum.2015.00601

17. Peterson BS, Rosen T, Dingman S, et al. Associations of Maternal Prenatal Drug Abuse With Measures of Newborn Brain Structure, Tissue Organization, and Metabolite Concentrations. *JAMA Pediatr*. 2020;174(9):831-842. doi:10.1001/jamapediatrics.2020.1622

18. Thomason ME, Palopoli AC, Jariwala NN, et al. Miswiring the brain: Human prenatal Δ9-tetrahydrocannabinol use associated with altered fetal hippocampal brain network connectivity. *Dev Cogn Neurosci*. 2021;51:101000. doi:10.1016/j.dcn.2021.101000

19. Baranger DAA, Miller AP, Gorelik AJ, et al. Prenatal cannabis exposure, the brain, and psychopathology during early adolescence. *Nat Ment Health*. 2024;2(8):975-986. doi:10.1038/s44220-024-00281-7

20. Evanski JM, Zundel CG, Baglot SL, et al. The First “Hit” to the Endocannabinoid System? Associations Between Prenatal Cannabis Exposure and Frontolimbic White Matter Pathways in Children. *Biol Psychiatry Glob Open Sci*. 2024;4(1):11-18. doi:10.1016/j.bpsgos.2023.09.005

21. Paul SE, Hatoum AS, Fine JD, et al. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study. *JAMA Psychiatry*. 2021;78(1):64-76. doi:10.1001/jamapsychiatry.2020.2902

22. Young-Wolff KC, Cortez CA, Nugent JR, et al. Sociodemographic differences in modes of cannabis use among pregnant individuals in Northern California. *Drug Alcohol Depend*. 2025;267:112546. doi:10.1016/j.drugalcdep.2024.112546

23. Dean DC, Tisdall MD, Wisnowski JL, et al. Quantifying brain development in the HEALthy Brain and Child Development (HBCD) Study: The magnetic resonance

imaging and spectroscopy protocol. *Dev Cogn Neurosci*. 2024;70:101452. doi:10.1016/j.dcn.2024.101452

24. Nelson CA, Frankeberger J, Chambers CD. An introduction to the HEALthy Brain and Child Development Study (HBCD) study. *Dev Cogn Neurosci*. 2024;69:101441. doi:10.1016/j.dcn.2024.101441

25. Goldstein E, Nervik K, Hagen S, et al. A socioecological framework for engaging substance-using pregnant persons in longitudinal research: Multi-stakeholder perspectives. *Neurotoxicol Teratol*. 2021;87:106997. doi:10.1016/j.ntt.2021.106997

26. Stone R. Pregnant women and substance use: fear, stigma, and barriers to care. *Health Justice*. 2015;3(1):2. doi:10.1186/s40352-015-0015-5

27. Harden BJ, McKelvey LM, Poehlmann JA, et al. The HEALthy Brain and Child Development Study (HBCD) experience: Recruiting and retaining diverse families in a longitudinal, multi-method early childhood study. *Dev Cogn Neurosci*. 2024;69:101421. doi:10.1016/j.dcn.2024.101421

28. Kingsley J, Andraka-Christou B, Shah SK, Spicer P, Newman S, Ossorio PN. Navigating ethical and legal challenges in the HEALthy Brain and Child Development Study: Lessons learned from the ethics, law, policy working group. *Dev Cogn Neurosci*. 2024;70:101460. doi:10.1016/j.dcn.2024.101460

29. Chambers C, Nelson C, Dale A, et al. HBCD Study Data Release 2.0. Published online 2026. doi:10.82525/VNYE-PE87

30. HBCD Consortium. HBCD Data Release Docs. *Zenodo*. Preprint posted online February 14, 2026. doi:10.5281/ZENODO.18637734

31. Uhlig K, Menon V, Schmid CH. Recommendations for reporting of clinical research studies. *Am J Kidney Dis Off J Natl Kidney Found*. 2007;49(1):3-7. doi:10.1053/j.ajkd.2006.10.012

32. National Institute on Drug Abuse. *NIDA Modified ASSIST.*

33. Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances — Systematic review and meta-analysis. *Addict Behav*. 2012;37(3):225-233. doi:10.1016/j.addbeh.2011.11.025

34. Martin-Willett R, Helmuth T, Abraha M, et al. Validation of a multisubstance online Timeline Followback assessment. *Brain Behav*. 2019;10(1):e01486. doi:10.1002/brb3.1486

35. Sobell L, Sobell M. Alcohol timeline followback (TLFB). In: *Handbook of Psychiatric Measures*. American Psychiatric Association.; 2000:477.

36. Psaras C. HBCD TLFB and ASSIST data cleaning scripts. Published online 2025. https://github.com/nbdc-datahub/hbcd-tlfb-su-flags?utm_source=chatgpt.com

37. Cox JL, Holden JM, Sagovsky R. Detection of Postnatal Depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry*. 1987;150(6):782-786. doi:10.1192/bjp.150.6.782

38. Doss RA, Lowmaster SE. Validation of the DSM-5 Level 1 Cross-Cutting Symptom Measure in a Community Sample. *Psychiatry Res*. 2022;318:114935. doi:10.1016/j.psychres.2022.114935

39. Hendrickson TJ, Reiners P, Moore LA, et al. BIBSNet: A Deep Learning Baby Image Brain Segmentation Network for MRI Scans. *BioRxiv Prepr Serv Biol*. Published online January 11, 2025:2023.03.22.533696. doi:10.1101/2023.03.22.533696

40. Cieslak M, Cook PA, He X, et al. QSIPrep: an integrative platform for preprocessing and reconstructing diffusion MRI data. *Nat Methods*. 2021;18(7):775-778. doi:10.1038/s41592-021-01185-5

41. Yeh FC, Panesar S, Fernandes D, et al. Population-Averaged Atlas of the Macroscale Human Structural Connectome and Its Network Topology. *NeuroImage*. 2018;178:57-68. doi:10.1016/j.neuroimage.2018.05.027

42. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics*. 2012;28(6):882-883. doi:10.1093/bioinformatics/bts034

43. Gonçalves PD, Woodruff JO, Pozzolo Pedro MO, et al. Investigating Links Between Prenatal Cannabis Exposure and Brain Development Using Magnetic Resonance Imaging Techniques: A Narrative Review. *Biol Psychiatry Glob Open Sci*. 2026;6(1):100624. doi:10.1016/j.bpsgos.2025.100624

44. RStudio Team. RStudio: Integrated Development for R. Published online 2020. http://www.rstudio.com/.

45. Fong C, Ratkovic M, Imai K, et al. CBPS: Covariate Balancing Propensity Score. Published online December 1, 2025. Accessed December 10, 2025. https://cran.r-project.org/web/packages/CBPS/index.html

46. ROSENBAUM PR, RUBIN DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41

47. Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. *J Am Stat Assoc*. 1984;79(387):516-524. doi:10.2307/2288398

48. Atkinson AC, Riani M, Corbellini A. The Box–Cox Transformation: Review and Extensions. *Stat Sci*. 2021;36(2):239-255. doi:10.1214/20-STS778

49. Box GEP, Cox DR. An Analysis of Transformations. *J R Stat Soc Ser B Methodol*. 1964;26(2):211-243. doi:10.1111/j.2517-6161.1964.tb00553.x

50. Raifman S, Biggs MA, Rocca C, Roberts SCM. Is legal recreational cannabis associated with cannabis use during pregnancy, beliefs about safety, and perceived community stigma? *Drug Alcohol Depend*. 2024;255:111079. doi:10.1016/j.drugalcdep.2023.111079

51. Huizink AC. Prenatal cannabis exposure and infant outcomes: Overview of studies. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;52:45-52. doi:10.1016/j.pnpbp.2013.09.014

52. Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure - The “first hit” to the endocannabinoid system. *Neurotoxicol Teratol*. 2016;58:5-14. doi:10.1016/j.ntt.2016.08.003

53. Bergin C, Cameron CE, Fleitz RS, Patel AV. Measuring prenatal drug exposure. *J Pediatr Nurs*. 2001;16(4):245-255. doi:10.1053/jpdn.2001.25534

54. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. *Eur Arch Psychiatry Clin Neurosci*. 2009;259(7):395-412. doi:10.1007/s00406-009-0027-z

55. Dubois J, Dehaene-Lambertz G, Kulikova S, Poupon C, Hüppi PS, Hertz-Pannier L. The early development of brain white matter: A review of imaging studies in fetuses, newborns and infants. *Neuroscience*. 2014;276:48-71. doi:10.1016/j.neuroscience.2013.12.044

56. Gao W, Lin W, Chen Y, et al. Temporal and spatial development of axonal maturation and myelination of white matter in the developing brain. *AJNR Am J Neuroradiol*. 2009;30(2):290-296. doi:10.3174/ajnr.A1363

57. Dean DC, O’Muircheartaigh J, Dirks H, et al. Modeling healthy male white matter and myelin development: 3 through 60 months of age. *NeuroImage*. 2014;84:742-752. doi:10.1016/j.neuroimage.2013.09.058

58. Grotheer M, Rosenke M, Wu H, et al. White matter myelination during early infancy is linked to spatial gradients and myelin content at birth. *Nat Commun*. 2022;13(1):997. doi:10.1038/s41467-022-28326-4

59. Ouyang M, Dubois J, Yu Q, Mukherjee P, Huang H. Delineation of early brain development from fetuses to infants with diffusion MRI and beyond. *NeuroImage*. 2019;185:836-850. doi:10.1016/j.neuroimage.2018.04.017

60. Tortoriello G, Morris CV, Alpar A, et al. Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. *EMBO J*. 2014;33(7):668-685. doi:10.1002/embj.201386035

61. Fu EL, Groenwold RHH, Zoccali C, Jager KJ, van Diepen M, Dekker FW. Merits and caveats of propensity scores to adjust for confounding. *Nephrol Dial Transplant*. 2019;34(10):1629-1635. doi:10.1093/ndt/gfy283

62. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. *Neurother J Am Soc Exp Neurother*. 2007;4(3):316-329. doi:10.1016/j.nurt.2007.05.011

63. Deoni SCL, Mercure E, Blasi A, et al. Mapping Infant Brain Myelination with Magnetic Resonance Imaging. *J Neurosci*. 2011;31(2):784-791. doi:10.1523/JNEUROSCI.2106-10.2011

64. Filimonova E, Amelina E, Sazonova A, Zaitsev B, Rzaev J. Assessment of normal myelination in infants and young children using the T1w/T2w mapping technique. *Front Neurosci*. 2023;17:1102691. doi:10.3389/fnins.2023.1102691

65. Morris AS, Hays-Grudo J, Zapata MI, Treat A, Kerr KL. Adverse and Protective Childhood Experiences and Parenting Attitudes: the Role of Cumulative Protection in Understanding Resilience. *Advers Resil Sci*. 2021;2(3):181-192. doi:10.1007/s42844-021-00036-8

66. Nolvi S, Merz EC, Kataja EL, Parsons CE. Prenatal Stress and the Developing Brain: Postnatal Environments Promoting Resilience. *Biol Psychiatry*. 2023;93(10):942-952. doi:10.1016/j.biopsych.2022.11.023

67. Ahmed S, Wang ZJ, Chia JM, Rollins NK. Correlation between diffusion kurtosis and NODDI metrics in neonates and young children. In: *Medical Imaging 2016: Biomedical Applications in Molecular, Structural, and Functional Imaging*. Vol 9788. SPIE; 2016:356-362. doi:10.1117/12.2217197

68. Chang YS, Owen JP, Pojman NJ, et al. White Matter Changes of Neurite Density and Fiber Orientation Dispersion during Human Brain Maturation. *PLOS ONE*. 2015;10(6):e0123656. doi:10.1371/journal.pone.0123656

69. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage*. 2012;61(4):1000-1016. doi:10.1016/j.neuroimage.2012.03.072

70. Deoni SC. Quantitative Relaxometry of the Brain. *Top Magn Reson Imaging TMRI*. 2010;21(2):101. doi:10.1097/RMR.0b013e31821e56d8

71. Alexander B, Kelly CE, Adamson C, et al. Changes in neonatal regional brain volume associated with preterm birth and perinatal factors. *NeuroImage*. 2019;185:654-663. doi:10.1016/j.neuroimage.2018.07.021

72. Sun H, Mehta S, Khaitova M, et al. Brain age prediction and deviations from normative trajectories in the neonatal connectome. *Nat Commun*. 2024;15(1):10251. doi:10.1038/s41467-024-54657-5

73. American College of Obstetrics & Gynecology. ACOG Clinical Consensus No. 10: Cannabis Use During Pregnancy and Lactation. *Obstet Gynecol*. 2025;146(4):600-611. doi:10.1097/AOG.0000000000006053

74. Daniels S, St. Pierre M, Sanchez T, Walsh Z. Physician Communication and Perceived Stigma in Prenatal Cannabis Use. *J Psychoactive Drugs*. 2023;55(3):290-298. doi:10.1080/02791072.2022.2076179

75. Nidey N, McAllister JM, Terplan M, Kair LR. Breastfeeding and Developmental Outcomes in Infants with Prenatal Cannabis Exposure: A Retrospective Cohort Study. *Breastfeed Med Off J Acad Breastfeed Med*. Published online December 23, 2025. doi:10.1177/15568253251409805